Ropidoxuridine - Shuttle Pharmaceuticals

Drug Profile

Ropidoxuridine - Shuttle Pharmaceuticals

Alternative Names: IMRT; Intensity Modulated RT; Intensity-Modulated Radiotherapy; IPdR - Shuttle Pharmaceuticals; Ropidoxuridine-Shuttle-Pharmaceuticals

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shuttle Pharmaceuticals
  • Developer National Cancer Institute (USA); Shuttle Pharmaceuticals
  • Class Antivirals; Pyrimidine nucleosides; Radiation-sensitising agents; Small molecules
  • Mechanism of Action DNA inhibitors; DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal cancer
  • Preclinical Glioblastoma; Sarcoma

Most Recent Events

  • 24 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top